@article {INOUE1077, author = {SHINGO INOUE and HIROMICHI KAWAIDA and RYO SAITO and YUKO NAKAYAMA and MASATO OHMORI and AYAKO KIMURA and KATSUTOSHI SHODA and SHINJI FURUYA and NAOHIRO HOSOMURA and HIDENORI AKAIKE and YOSHIHIKO KAWAGUCHI and HIDETAKE AMEMIYA and MAKOTO SUDO and HIROSHI KONO and DAISUKE ICHIKAWA}, title = {Clinical Significance of Past History of Breast Cancer Screening for the Prognosis of Triple Negative Breast Cancer}, volume = {41}, number = {2}, pages = {1077--1082}, year = {2021}, doi = {10.21873/anticanres.14865}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: This study examined the prognostic impact of the past history of breast cancer screening within the last 2 years (PH-BCS), for patients with triple negative breast cancer (TNBC), a subtype that carries extremely poor prognosis. Patients and Methods: Eighty-six consecutive cases with TNBC, who underwent surgery at our faculty from 2009 to 2015, were divided into two groups according to PH-BCS. Prognostic analyses for disease-free survival and overall survival between the two groups were performed. Results: The positive PH-BCS group (n=44) had a significantly better prognoses than the negative PH-BCS group (n=42) (p\<0.001). No recurrent cases were observed in the positive PH-BCS group. In the negative PH-BCS group, tumor and node status and chemotherapy were indicated as significant prognostic factors, and further step-wise multivariate analysis revealed only node status as a significant prognostic factor. Conclusion: Breast cancer screening at least every 2 years may improve the prognosis of TNBC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/2/1077}, eprint = {https://ar.iiarjournals.org/content/41/2/1077.full.pdf}, journal = {Anticancer Research} }